The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Combined Inhibition of Tumor Necrosis Factor α and Interleukin‐17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody
Abstract
Objective: Rheumatoid arthritis therapies that are based on inhibition of a single cytokine, e.g., tumor necrosis factor α (TNFα) or interleukin‐6 (IL‐6), produce clinically meaningful responses in only about half of the treated patients. This study was undertaken to investigate whether combined inhibition of TNFα and IL‐17 has additive or synergistic effects in the suppression of mesenchymal cell activation in vitro and inflammation and tissue destruction in arthritis in vivo. Methods: Cultures of human fibroblast‐like synoviocytes (FLS) were stimulated with TNFα, IL‐17, or a combination of both. Single/combined neutralizing antibodies against TNFα and IL‐17 were used to examine in vitro cytokine responses and in vivo development of arthritis and bone and cartilage destruction in TNFα‐transgenic mice. Bispecific anti–TNFα/IL‐17 antibodies were designed, and their potential to block cytokine responses in human FLS was tested. Results: TNFα and IL‐17 had additive/synergistic effects in promoting production of IL‐6, IL‐8, and granulocyte colony‐stimulating factor, as well as matrix metalloproteinases, in FLS. Bispecific anti–TNFα/IL‐17 antibodies showed superior efficacy in blocking cytokine and chemokine responses in vitro. Furthermore, dual versus single inhibition of both cytokines using neutralizing antibodies was more effective in inhibiting the development of inflammation and bone and cartilage destruction in arthritic mice. Conclusion: Combined blockade of TNFα and IL‐17 was more effective than single blockade in inhibiting cytokine, chemokine, and matrix enzyme responses from human mesenchymal cells and in blocking tissue destruction associated with arthritis, and additionally showed a positive impact on rebalance of bone homeostasis. Bispecific anti–TNFα/IL‐17 antibodies may have superior efficacy in the treatment of arthritis and may overcome the limited therapeutic responses obtained with single cytokine neutralization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514
Self-citationSato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061775 · Cited by 1,554
Ziolkowska, M., Koc, A., Luszczykiewicz, G., Ksiezopolska-Pietrzak, K., Klimczak, E., Chwalinska-Sadowska, H., & Maslinski, W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2832 · Cited by 580
Kirkham, B. W., Lassere, M. N., Edmonds, J. P., Juhasz, K. M., Bird, P. A., Lee, C. S., Shnier, R., & Portek, I. J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21749 · Cited by 336
Cited by
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Kalliolias, G. D., & Ivashkiv, L. B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.169 · Cited by 1,387
T H 2 and T H 17 inflammatory pathways are reciprocally regulated in asthma
Choy, D. F., Hart, K. M., Borthwick, L. A., Shikotra, A., Nagarkar, D. R., Siddiqui, S., Jia, G., Ohri, C. M., Doran, E., Vannella, K. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab3142 · Cited by 450
IL-17 in Chronic Inflammation: From Discovery to Targeting
Beringer, A., Noack, M., & Miossec, P. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.01.001 · Cited by 402
Bioactive Materials for Bone Regeneration: Biomolecules and Delivery Systems
Szwed-Georgiou, A., Płociński, P., Kupikowska-Stobba, B., Urbaniak, M. M., Rusek-Wala, P., Szustakiewicz, K., Piszko, P., Krupa, A., Biernat, M., Gazińska, M., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00609 · Cited by 269
Metadata
- Authors
- Fischer, J. A. A., Hueber, A. J., Wilson, S., Galm, M., Baum, W., Kitson, C., Auer, J., Lorenz, S. H., Moelleken, J., Bader, M., Tissot, A. C., Tan, S., Seeber, S., & Schett, G.
- Venue
- Arthritis & Rheumatology
- Publisher
- Wiley
- Published
- 2014-12-27
- Volume
- 67
- Issue
- 1
- Pages
- 51-62
- ISSN
- 2326-5191 (ISSN-L)
- 2326-5205
- OpenAlex
- W1564498610
- Cited by
- 162
- References
- 4
- FWCI
- 16.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.